Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for DIVISLAB
Revenue projections for DIVISLAB

DIVISLAB is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.

Financial Ratios:

currentRatio 0.000000
forwardPE 53.788498
debtToEquity 0.584000
earningsGrowth -0.010000
revenueGrowth 0.123000
grossMargins 0.616540
operatingMargins 0.296470
trailingEps 93.110000
forwardEps 116.958090

Divi's Laboratories Limited's high forward PE suggests the stock may be overvalued, potentially limiting future price gains and increasing the risk of a price correction. Investors should consider this metric carefully alongside other fundamentals to assess the stock's true value and growth potential.
With positive gross and operating margins, Divi's Laboratories Limited demonstrates strong profitability. This reflects the company's ability to manage costs and maintain healthy profits, showcasing effective operational efficiency and financial stability.
DIVISLAB's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that DIVISLAB's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.

Price projections:

Price projections for DIVISLAB
Price projections for DIVISLAB

Divi's Laboratories Limited's price projections have been gradually revised upward, reflecting increased confidence in the company's future performance. This trend suggests analysts expect Divi's Laboratories Limited to achieve greater success in the coming periods.

Insider Transactions:

Insider Transactions for DIVISLAB
Insider Transactions for DIVISLAB


8 separate sales of Divi's Laboratories Limited shares were executed, with the market price hovering at 6399.481262207031.There were no sell transactions during the given timeframe.With more buying than selling around DIVISLAB's current price, investors could be expressing optimism. This trend may suggest that the market expects favorable outcomes for the stock, leading to an increased demand at these levels.

Recommendation changes over time:

Recommendations trend for DIVISLAB
Recommendations trend for DIVISLAB


The recent buy bias from analysts suggests DIVISLAB is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, DIVISLAB appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.